News & Events

Simpson Thacher represented Celltrion Healthcare Co., Ltd. (“Celltrion Healthcare”) in connection with the initial public offering of 24,604,000 shares of its common stock. The offering raised Won 1.01 trillion (approximately US$900 million) in gross proceeds for Celltrion Healthcare. The common shares of Celltrion Healthcare were listed on the KRX KOSDAQ Market of the Korea Exchange and offered by Celltrion Healthcare as a registered IPO in Korea and in reliance on exemptions under the U.S. Securities Act of 1933, as amended, including Rule 144A and Regulation S, outside Korea. Mirae Asset Daewoo acted as global coordinator and joint bookrunner, UBS acted as joint bookrunner, and Macquarie, Hanwha Investment & Securities and Shinhan Investment Corp. acted as co-managers.  

Celltrion Healthcare is a leading global marketing and distribution company based in Korea specializing in the biosimilar market.

The Simpson Thacher team for the transaction included Youngjin Sohn, John Hahn and Joongwon Park (Corporate); and Jonathan Cantor and Sarah Katz (Tax).